Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes-Reference-Cited by-同舟云学术

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes

Published:2021-02-01 Issue:2 Volume:6 Page:148
ISSN:2380-6583
Container-title:JAMA Cardiology
language:en
Short-container-title:JAMA Cardiol

Author:

McGuire Darren K.¹,Shih Weichung J.²³,Cosentino Francesco⁴,Charbonnel Bernard⁵,Cherney David Z. I.⁶,Dagogo-Jack Samuel⁷,Pratley Richard⁸,Greenberg Michelle⁹,Wang Shuai⁹,Huyck Susan¹⁰,Gantz Ira¹⁰,Terra Steven G.¹¹,Masiukiewicz Urszula⁹,Cannon Christopher P.¹²

Affiliation:

1. Department of Internal Medicine, University of Texas Southwestern Medical Center, and Parkland Health and Hospital System, Dallas

2. Rutgers School of Public Health, Rutgers Biomedical and Health Sciences, Piscataway, New Jersey

3. Rutgers Cancer Institute of New Jersey, New Brunswick

4. Unit of Cardiology, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden

5. Department of Endocrinology, University of Nantes, Nantes, France

6. Division of Nephrology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada

7. Department of Medicine, University of Tennessee Health Science Center, Memphis

8. AdventHealth Translational Research Institute, Orlando, Florida

9. Pfizer Inc, Groton, Connecticut

10. Merck & Co Inc, Kenilworth, New Jersey

11. Pfizer Inc, Andover, Massachusetts

12. Cardiovascular Division, Brigham and Women’s Hospital, Baim Institute for Clinical Research, Harvard Medical School, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

Link

https://jamanetwork.com/journals/jamacardiology/articlepdf/2771459/jamacardiology_mcguire_2020_oi_200067_1612387620.89037.pdf

Reference47 articles.

1. Mortality and cardiovascular disease in type 1 and type 2 diabetes.;Rawshani;N Engl J Med,2017

2. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes.;Rawshani;N Engl J Med,2018

3. The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions.;Ofstad;Heart Fail Rev,2018

4. Heart failure considerations of antihyperglycemic medications for type 2 diabetes.;Standl;Circ Res,2016

5. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020.;American Diabetes Association;Diabetes Care,2020

Cited by 760 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEART;The Lancet Regional Health - Europe;2024-10

2. Heart failure with preserved ejection fraction epidemiology, pathophysiology, diagnosis and treatment strategies;International Journal of Cardiology;2024-10

3. Empagliflozin-A Sodium Glucose Co-transporter-2 Inhibitor: Overview of its Chemistry, Pharmacology, and Toxicology;Current Diabetes Reviews;2024-10

4. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases;Metabolism;2024-10

5. Timing of sodium–glucose cotransporter 2 inhibitor initiation and post‐discharge outcomes in acute heart failure with diabetes: A population‐based cohort study;European Journal of Heart Failure;2024-09-12